Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Aug 08, 2006

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

1. Registrant Name: RICCHETTI INCORPORATED 1001 G STREET NW SUITE 600 EAST, WASHINGTON, DC 20001 3. Principal place of business (if different from line 2): Country City: SAME State/Zip(or Country): 4. Contact Name: JAMES HEIMBACH Telephone: 202-879-9367 E-mail (optional): jay@ricchettiinc.com Senate ID #: 62778-36 House ID #: 35395005 7. Client Name: Self ELI LILLY AND COMPANY TYPE OF REPORT ____ Midyear (January 1 - June 30): 🛛 OR Year End (July 1 - December 31): 🗌 8. Year 2006 9. Check if this filing amends a previously filed version of this report: 10. Check if this is a Termination Report: => Termination Date: 11. No Lobbying Activity: 🔲 INCOME OR EXPENSES Complete Either Line 12 OR Line 13 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000: \$10,000 or more: X => Income (nearest \$20,000): 60,000.00 Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000: \$10,000 or more: => Expenses (nearest \$20,000); 14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options.

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: ADV (one per page)
- 16. Specific lobbying issues:

Issues relating to the direct-to-consumer advertising of prescription drugs

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: RICCHETTI, JEFF Covered Official Position (if applicable): Name: RICCHETTI, STEVE Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code: BUD (one per page)
- 16. Specific lobbying issues:

Issues pertaining to the Medicaid funding debate, determination of Medicaid drug pricing, authorized generics, and extension of rebates to Medicaid managed care.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: RICCHETTI, JEFF Covered Official Position (if applicable): Name: RICCHETTI, STEVE Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: CPT (one per page)
- 16. Specific lobbying issues:

Issues regarding proposed reforms of the US patent system

17. House(s) of Congress and Federal agencies contacted:

US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ALBEE, LUKE

Covered Official Position (if applicable): CHIEF OF STAFF TO SENATOR PATRICK LEAHY (VT)

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: HCR (one per page)
- 16. Specific lobbying issues:

Issues pertaining to the importation of prescription drugs, including: S. 334, the Pharmaceutical Market Access and Drug Saefty Act S. 184, the Safe Import Act S, 109, the Pharmaceutical Market Access Act HR 1626, the Medicare Prescription Drug Improvement Act

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: RICCHETTI, JEFF Covered Official Position (if applicable): Name: RICCHETTI, STEVE Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: MMM (one per page)
- 16. Specific lobbying issues:

Issues pertaining to the implementation of the Medicare Modernization Act, including issues affecting patient assistance programs Issues pertaining to the reform of the Medicare Modernization Act, including work on: S 445, Medicare Prescription Drug Price Reduction Act S 2354, the Medicare Prescription Drug Gap Reducation Act

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: RICCHETTI, JEFF Covered Official Position (if applicable): Name: RICCHETTI, STEVE

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Aug 08, 2006

Printed Name and Title: James Heimbach, Vice President -